What could you do with 15 letters?
Show her the world.

Give your patients a chance to gain as many lines as possible.

Lucentis is the first and only therapy proven to deliver a 3-line gain in up to 41% of patients at 2 years with monthly dosing (vs 4% with sham and 6% withverteporfin PDT)

Nearly all Lucentis-treated patients – 90% – maintained vision at 2 years (vs 53% with sham and 66% with verteporfin PDT)

Brand name: Lucentis
Generic name/category: Ranibizumab, Ophtalmology
Company: Genentech
Country/Market: USA, North America
Indication(s)/use: neovascular (wet) age-related macular degeneration
Target: Healthcare Professionals (HCP)
Tagline: Lines gained. Lives changed.
Publication: Ophtalmology Times June 2009

To see all of this brand’s ads on AdPharm, click here

La gratuité en santé. Mon oeil!
Free healthcare treatments. No way!

Click here to listen to radio spot

French radio ad to force the Quebec Government, by getting people to write to their deputy, to reimburse Lucentis for Quebec residents.

People were encouraged to visit CampagneMonOeil.ca where they could find an editable text in a web form to send directly to their deputy.

Ranibizumab (trade name Lucentis) is a monoclonal antibody fragment derived from the same parent murine antibody as bevacizumab (Avastin). It is much smaller than the parent molecule and has been affinity matured to provide stronger binding to VEGF-A. It is an anti-angiogenic that has been approved to treat the “wet” type of age-related macular degeneration (ARMD), a common form of age-related vision loss.

Ranibizumab was developed by Genentech and is marketed in the United States by Genentech and elsewhere by Novartis, under the brand name Lucentis.

More on Wikipedia

Brand name: CampagneMonOeil.ca for Lucentis
Generic name/category: Ranibizumab
Company: Novartis
Country/Market: Quebec province, Canada
Indication(s)/use: age-related macular degeneration (ARMD)
Target: Consumers (DTC)
Tagline: La gratuité en santé. Mon oeil!
Publication: Quebec radio stations may 2009